,Gene,Gene synonym,Ensembl,Gene description,Chromosome,Position,Protein class,Evidence,Antibody,Reliability (IH),Reliability (Mouse Brain),Reliability (IF),Subcellular location,Prognostic p-value,RNA cancer category,RNA tissue category,RNA TS,RNA TS TPM,TPM max in non-specific,RNA cell line category,RNA CS,RNA CS TPM
0,KNG1,"BDK, BK, KNG",ENSG00000113889,Kininogen 1,3,186717276-186743954,"Disease related genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"HPA001616, HPA001645, CAB009809",Enhanced,,,,Liver cancer:1.28e-6 (favourable),Tissue enriched,Group enriched,994,kidney: 522.4;liver: 1864.6,rectum: 1.2,Cell line enhanced,,CACO-2: 1.5;Hep G2: 1.2;RH-30: 1.3
1,UGT1A9,"HLUGP4, LUGP4, UGT1AI",ENSG00000241119,UDP glucuronosyltransferase family 1 member A9,2,233671853-233773300,"Cancer-related genes, Enzymes, Predicted membrane proteins",Evidence at protein level,,,,,,Renal cancer:5.04e-5 (unfavourable),Group enriched,Group enriched,592,kidney: 465.5;liver: 93.3,"cerebral cortex,colon: 0.4",Cell line enhanced,,A549: 1.2
2,ACSM2A,"A-923A4.1, ACSM2, MGC150530",ENSG00000183747,Acyl-CoA synthetase medium-chain family member 2A,16,20451461-20487667,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA057699,Supported,,,,Liver cancer:1.41e-5 (favourable),Group enriched,Group enriched,580,kidney: 285.2;liver: 185.7,cerebral cortex: 0.4,Cell line enhanced,,Hep G2: 1.3
3,HAO2,"GIG16, HAOX2",ENSG00000116882,Hydroxyacid oxidase 2,1,119368779-119394130,"Enzymes, Predicted intracellular proteins",Evidence at protein level,,,,,,Renal cancer:4.92e-4 (favourable),Group enriched,Group enriched,300,kidney: 317.5;liver: 219.8,"adrenal gland,breast: 0.8",Not detected,,
4,BHMT,BHMT1,ENSG00000145692,Betaine--homocysteine S-methyltransferase,5,79111779-79132290,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA038285, HPA058310",Enhanced,,Supported,Cytosol,Liver cancer:7.32e-4 (favourable),Tissue enhanced,Group enriched,225,kidney: 788.8;liver: 563.6,urinary bladder: 3.0,Cell line enhanced,,Hep G2: 2.4;NTERA-2: 1.4;SCLC-21H: 1.1
5,CYP3A4,CYP3A3,ENSG00000160868,Cytochrome P450 family 3 subfamily A member 4,7,99756960-99784265,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB033671, HPA072245",Enhanced,,Uncertain,Cytosol,,Tissue enriched,Group enriched,199,duodenum: 826.8;liver: 2451.8;small intestine: 971.1,adrenal gland: 7.1,Cell line enhanced,,BEWO: 1.8;NB-4: 1.3;RPMI-8226: 2.2;SCLC-21H: 1.4;SH-SY5Y: 2.4
6,CYP4A11,"CYP4A2, CYP4AII",ENSG00000187048,Cytochrome P450 family 4 subfamily A member 11,1,46929177-46941484,"Enzymes, Predicted membrane proteins",Evidence at protein level,,,,,,,Tissue enriched,Group enriched,183,kidney: 232.3;liver: 448.3,gallbladder: 1.8,Not detected,,
7,ACSM2B,"ACSM2, HXMA, HYST1046",ENSG00000066813,Acyl-CoA synthetase medium-chain family member 2B,16,20536226-20576427,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA057699,Supported,,,,Liver cancer:3.31e-4 (favourable),Group enriched,Group enriched,136,kidney: 426.7;liver: 262.0,thyroid gland: 2.5,Cell line enhanced,,AF22: 2.8;Hep G2: 3.7
8,APOB,,ENSG00000084674,Apolipoprotein B,2,21001429-21044073,"Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"CAB016070, HPA049793",Supported,,Supported,Vesicles<br>Cytosol,,Tissue enriched,Group enriched,120,duodenum: 182.8;liver: 618.9;small intestine: 333.2,adipose tissue: 3.1,Cell line enriched,25.0,Hep G2: 734.4
9,CREB3L3,CREB-H,ENSG00000060566,CAMP responsive element binding protein 3 like 3,19,4153601-4173054,"Predicted intracellular proteins, Predicted membrane proteins, Transcription factors",Evidence at protein level,"HPA040671, HPA056228",Enhanced,,,,Renal cancer:3.53e-6 (unfavourable),Tissue enriched,Group enriched,104,duodenum: 241.6;liver: 61.0;small intestine: 278.7,"colon,stomach: 1.8",Cell line enhanced,,HDLM-2: 44.9;Hep G2: 10.3;U-266/70: 7.7
10,PRODH2,HSPOX1,ENSG00000250799,Proline dehydrogenase 2,19,35799988-35813299,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA051287,Approved,,Supported,Nucleoplasm<br>Cytosol,,Group enriched,Group enriched,96,kidney: 132.8;liver: 45.1,testis: 0.9,Cell line enriched,14.0,Hep G2: 21.4
11,HPD,"4-HPPD, 4HPPD, GLOD3, PPD",ENSG00000158104,4-hydroxyphenylpyruvate dioxygenase,12,121839527-121863596,"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA038321, HPA038322",Enhanced,,Uncertain,Nuclear speckles,,Tissue enriched,Group enriched,86,kidney: 529.9;liver: 1293.2,seminal vesicle: 10.5,Cell line enriched,24.0,Hep G2: 349.1
12,SLC22A7,"NLT, OAT2",ENSG00000137204,Solute carrier family 22 member 7,6,43295694-43305538,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA030220,Approved,,,,"Liver cancer:5.48e-6 (favourable), Renal cancer:8.98e-4 (favourable)",Tissue enriched,Group enriched,73,kidney: 50.3;liver: 167.8,testis: 1.4,Cell line enriched,14.0,Hep G2: 6.7
13,CRP,PTX1,ENSG00000132693,C-reactive protein,1,159712289-159714589,"Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB005036, HPA027367, HPA027396",Supported,,,,Renal cancer:4.17e-10 (unfavourable),Tissue enriched,Group enriched,67,gallbladder: 172.9;liver: 532.1,endometrium: 5.2,Cell line enhanced,,EFO-21: 5.9;HDLM-2: 5.8;U-2 OS: 4.4;U-266/84: 7.5
14,C4BPA,C4BP,ENSG00000123838,Complement component 4 binding protein alpha,1,207104262-207144972,"Plasma proteins, Predicted secreted proteins",Evidence at protein level,"HPA000926, HPA001578",Enhanced,,,,"Endometrial cancer:6.37e-5 (favourable), Liver cancer:2.24e-4 (favourable)",Tissue enriched,Group enriched,65,liver: 997.5;lung: 262.3,"cervix, uterine: 9.6",Cell line enriched,6.0,Hep G2: 25.8
15,IGFBP1,"AFBP, hIGFBP-1, IBP1, IGF-BP25, PP12",ENSG00000146678,Insulin like growth factor binding protein 1,7,45888357-45893668,"Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"CAB004445, HPA046972, HPA050640",Enhanced,,Approved,Golgi apparatus,"Renal cancer:6.90e-11 (unfavourable), Lung cancer:1.03e-4 (unfavourable), Stomach cancer:6.64e-4 (unfavourable)",Tissue enriched,Group enriched,52,endometrium: 120.4;liver: 563.0;placenta: 265.8,fallopian tube: 6.0,Group enriched,8.0,Hep G2: 33.4;U-2197: 71.7;U-87 MG: 128.8
16,DAO,DAMOX,ENSG00000110887,D-amino acid oxidase,12,108858932-108901043,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA038653, HPA038654",Enhanced,,,,Renal cancer:4.11e-4 (favourable),Tissue enriched,Group enriched,36,kidney: 89.8;liver: 74.1,rectum: 2.2,Not detected,,
17,TM4SF4,il-TMP,ENSG00000169903,Transmembrane 4 L six family member 4,3,149473974-149503281,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA046430,Enhanced,,Approved,Plasma membrane<br>Cytosol,,Group enriched,Group enriched,34,duodenum: 579.6;gallbladder: 1319.6;liver: 346.9;small intestine: 504.0,stomach: 20.2,Group enriched,6.0,A549: 19.4;RPTEC TERT1: 24.4
18,AGXT2,AGT2,ENSG00000113492,Alanine--glyoxylate aminotransferase 2,5,34998101-35048135,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA037382,Enhanced,,,,Renal cancer:7.47e-4 (favourable),Group enriched,Group enriched,33,kidney: 197.9;liver: 59.3,small intestine: 3.9,Not detected,,
19,UGT1A1,"GNT1, UGT1, UGT1A",ENSG00000241635,UDP glucuronosyltransferase family 1 member A1,2,233760248-233773299,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins",Evidence at protein level,,,,,,,Tissue enriched,Group enriched,33,duodenum: 199.5;liver: 155.8;small intestine: 81.9,kidney: 4.3,Cell line enhanced,,HaCaT: 12.7;PC-3: 6.0;RT4: 27.4
20,ABCG5,STSL,ENSG00000138075,ATP binding cassette subfamily G member 5,2,43812472-43838865,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA016514,,,Approved,Nucleus,Liver cancer:2.60e-5 (favourable),Tissue enriched,Group enriched,32,duodenum: 56.5;liver: 28.4;small intestine: 56.2,gallbladder: 1.4,Cell line enriched,37.0,Hep G2: 6.3
21,DIO1,TXDI1,ENSG00000211452,Iodothyronine deiodinase 1,1,53891239-53911086,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,,,,,,Thyroid cancer:5.44e-4 (unfavourable),Group enriched,Group enriched,30,kidney: 147.5;liver: 94.9;thyroid gland: 434.9,fallopian tube: 7.5,Group enriched,20.0,Hep G2: 23.0;SK-BR-3: 59.3
22,ALDH8A1,ALDH12,ENSG00000118514,Aldehyde dehydrogenase 8 family member A1,6,134917390-134950122,Predicted intracellular proteins,Evidence at protein level,"HPA026292, HPA055414",Enhanced,,Supported,Centrosome,Renal cancer:9.87e-4 (favourable),Group enriched,Group enriched,29,kidney: 74.3;liver: 127.7,cerebral cortex: 3.4,Mixed,,
23,OTC,,ENSG00000036473,Ornithine carbamoyltransferase,X,38352545-38421450,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA000243, HPA000570",Enhanced,,Supported,Mitochondria,,Tissue enriched,Group enriched,26,duodenum: 114.4;liver: 195.4;small intestine: 96.9,colon: 5.3,Not detected,,
24,SLC28A1,CNT1,ENSG00000156222,Solute carrier family 28 member 1,15,84884654-84945796,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA019551,Enhanced,,,,,Group enriched,Group enriched,26,duodenum: 37.9;kidney: 49.4;liver: 35.4;small intestine: 53.6,placenta: 1.7,Not detected,,
25,ABCG8,GBD4,ENSG00000143921,ATP binding cassette subfamily G member 8,2,43838964-43878466,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA019556,Uncertain,,Approved,Vesicles,,Tissue enriched,Group enriched,25,duodenum: 50.0;liver: 34.0;small intestine: 55.5,gallbladder: 1.8,Cell line enriched,44.0,Hep G2: 6.9
26,ALDOB,,ENSG00000136872,"Aldolase, fructose-bisphosphate B",9,101420578-101435823,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA002198, CAB020827",Enhanced,,,,,Tissue enriched,Group enriched,23,duodenum: 3705.7;kidney: 6574.8;liver: 5092.2;small intestine: 5611.2,gallbladder: 231.1,Cell line enhanced,,BEWO: 16.8;NB-4: 10.8;RPMI-8226: 13.6;SH-SY5Y: 17.3
27,CPS1,,ENSG00000021826,Carbamoyl-phosphate synthase 1,2,210477682-210679107,"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB003781, HPA021400",Enhanced,,Approved,Nucleoli,Liver cancer:6.93e-5 (favourable),Tissue enriched,Group enriched,23,duodenum: 234.5;liver: 697.8;small intestine: 144.1,testis: 15.3,Cell line enhanced,,HeLa: 249.1;SK-BR-3: 84.1
28,UPB1,BUP1,ENSG00000100024,Beta-ureidopropionase 1,22,24494107-24528390,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA000728,Enhanced,,,,Liver cancer:2.30e-7 (favourable),Tissue enriched,Group enriched,23,kidney: 51.2;liver: 161.7,testis: 4.6,Cell line enhanced,,CACO-2: 6.0;NB-4: 1.9;THP-1: 2.7;U-937: 3.5
29,DPYS,DHPase,ENSG00000147647,Dihydropyrimidinase,8,104330324-104467053,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA024785,Enhanced,,,,,Group enriched,Group enriched,22,kidney: 200.4;liver: 246.2,gallbladder: 10.1,Not detected,,
30,ANGPTL8,"C19orf80, RIFL, TD26",ENSG00000130173,Angiopoietin like 8,19,11237450-11241943,"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA042131,,,Approved,Nucleoplasm<br>Golgi apparatus,Renal cancer:1.84e-6 (unfavourable),Tissue enriched,Group enriched,20,adipose tissue: 13.7;liver: 63.8,epididymis: 1.9,Group enriched,28.0,Hep G2: 24.9;MCF7: 16.3
31,FTCD,,ENSG00000160282,Formimidoyltransferase cyclodeaminase,21,46136262-46155567,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA020073, HPA030928, HPA030929, HPA036114",Enhanced,,Approved,Plasma membrane<br>Cytosol,"Pancreatic cancer:6.78e-5 (favourable), Liver cancer:1.70e-4 (favourable), Renal cancer:5.78e-4 (favourable)",Tissue enriched,Group enriched,18,kidney: 100.2;liver: 184.7,testis: 7.7,Cell line enriched,24.0,Hep G2: 62.7
32,C4BPB,C4BP,ENSG00000123843,Complement component 4 binding protein beta,1,207088842-207099993,"Plasma proteins, Predicted secreted proteins",Evidence at protein level,HPA051620,Approved,,,,,Tissue enriched,Group enriched,16,liver: 241.3;ovary: 52.0,placenta: 8.9,Group enriched,15.0,CACO-2: 94.2;HeLa: 31.3;Hep G2: 101.7
33,CYP4A22,,ENSG00000162365,Cytochrome P450 family 4 subfamily A member 22,1,47137435-47149741,"Enzymes, Predicted membrane proteins",Evidence at protein level,,,,,,,Tissue enriched,Group enriched,16,kidney: 33.5;liver: 109.1,epididymis: 4.5,Cell line enriched,5.0,RH-30: 1.2
34,MTTP,"ABL, MTP",ENSG00000138823,Microsomal triglyceride transfer protein,4,99563761-99623999,"Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA051170, HPA054862",Uncertain,,Approved,Cytosol,,Tissue enriched,Group enriched,16,duodenum: 236.3;liver: 133.9;small intestine: 292.6,testis: 13.5,Cell line enhanced,,AF22: 10.2;Hep G2: 8.0
35,HFE2,"haemojuvelin, hemojuvelin, HFE2A, HJV, JH, RGMC",ENSG00000168509,Hemochromatosis type 2 (juvenile),1,146017468-146036746,"Disease related genes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,,,,,,,Tissue enriched,Group enriched,15,heart muscle: 45.4;liver: 123.4;skeletal muscle: 212.6,esophagus: 8.6,Cell line enhanced,,HSkMC: 1.1;K-562: 1.4
36,GOLGA6B,,ENSG00000215186,Golgin A6 family member B,15,72654738-72666394,Predicted intracellular proteins,Evidence at protein level,"HPA044978, HPA050087",Supported,,,,,Not detected,Group enriched,14,liver: 1.9;testis: 5.3,cerebral cortex: 0.2,Not detected,,
37,PROZ,PZ,ENSG00000126231,"Protein Z, vitamin K dependent plasma glycoprotein",13,113158654-113172383,"Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,HPA052006,Enhanced,,,,Liver cancer:3.46e-4 (favourable),Tissue enriched,Group enriched,14,kidney: 14.5;liver: 27.4,testis: 1.5,Cell line enhanced,,HaCaT: 1.9;Hep G2: 2.4
38,UPP2,"UDRPASE2, UP2, UPASE2",ENSG00000007001,Uridine phosphorylase 2,2,157876702-158136154,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA035225, HPA035226",,,Approved,Nucleus<br>Vesicles<br>Mitochondria,,Tissue enriched,Group enriched,14,kidney: 52.2;liver: 14.3,cerebral cortex: 2.4,Not detected,,
39,GLYATL1,"FLJ34646, MGC15397",ENSG00000166840,Glycine-N-acyltransferase like 1,11,58905398-59043527,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA039501,Supported,,Uncertain,Golgi apparatus<br>Cytosol,"Renal cancer:3.03e-5 (favourable), Liver cancer:3.69e-4 (favourable)",Group enriched,Group enriched,13,kidney: 145.2;liver: 298.1,prostate: 17.4,Cell line enhanced,,CACO-2: 1.6;Daudi: 3.5;RPTEC TERT1: 1.2;U-2197: 1.1
40,NAT2,AAC2,ENSG00000156006,N-acetyltransferase 2,8,18391245-18401218,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA043704,Uncertain,,,,Colorectal cancer:4.61e-5 (favourable),Tissue enhanced,Group enriched,13,colon: 14.4;duodenum: 32.7;liver: 62.4;rectum: 14.0;small intestine: 27.1,smooth muscle: 2.3,Cell line enhanced,,RT4: 1.2;SCLC-21H: 2.5;SK-BR-3: 1.0
41,UGT2B7,UGT2B9,ENSG00000171234,UDP glucuronosyltransferase family 2 member B7,4,69051363-69112987,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA045108,Uncertain,,,,"Colorectal cancer:7.65e-5 (favourable), Renal cancer:3.79e-4 (favourable), Urothelial cancer:5.38e-4 (favourable)",Group enriched,Group enriched,13,kidney: 1326.3;liver: 825.7,fallopian tube: 79.7,Cell line enhanced,,EFO-21: 73.2;RPTEC TERT1: 235.7;U-2197: 40.2
42,CNDP1,"CN1, CPGL2, HsT2308, MGC10825",ENSG00000150656,Carnosine dipeptidase 1,18,74534440-74587212,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA008933,Enhanced,,,,,Group enriched,Group enriched,12,cerebral cortex: 101.7;liver: 23.0,duodenum: 5.1,Cell line enriched,68.0,U-266/84: 57.1
43,HABP2,"FSAP, HABP, HGFAL, PHBP",ENSG00000148702,Hyaluronan binding protein 2,10,113550837-113589602,"Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA019518,Approved,,,,,Tissue enriched,Group enriched,12,gallbladder: 55.8;liver: 225.6,stomach: 11.3,Cell line enriched,5.0,RPTEC TERT1: 38.3
44,MOGAT2,"DGAT2L5, FLJ22644, MGAT2",ENSG00000166391,Monoacylglycerol O-acyltransferase 2,11,75717819-75732958,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA028834,Uncertain,,,,,Tissue enhanced,Group enriched,12,colon: 12.5;duodenum: 37.2;liver: 12.1;rectum: 12.5;small intestine: 43.6,appendix: 1.9,Group enriched,6.0,Hep G2: 2.7;RPMI-8226: 1.8
45,SLC39A5,,ENSG00000139540,Solute carrier family 39 member 5,12,56230049-56237846,"Disease related genes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters",Evidence at protein level,HPA018423,,,Approved,Nucleoplasm<br>Vesicles<br>Cytosol,Renal cancer:5.05e-4 (favourable),Tissue enhanced,Group enriched,12,colon: 73.2;duodenum: 240.2;kidney: 115.0;liver: 86.0;pancreas: 53.1;rectum: 48.9;small intestine: 240.4,gallbladder: 10.0,Group enriched,62.0,CACO-2: 33.1;Hep G2: 39.7
46,CLDN14,DFNB29,ENSG00000159261,Claudin 14,21,36460621-36576569,"Disease related genes, Predicted membrane proteins",Evidence at protein level,HPA054707,,,Uncertain,Vesicles,Liver cancer:1.53e-4 (favourable),Tissue enriched,Group enriched,11,kidney: 3.6;liver: 9.5,gallbladder: 0.6,Cell line enriched,18.0,HDLM-2: 205.9
47,CYP2C18,"CPCI, CYP2C, CYP2C17, P450IIC17",ENSG00000108242,Cytochrome P450 family 2 subfamily C member 18,10,94683621-94736190,"Enzymes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,,,,,,,Tissue enhanced,Group enriched,11,duodenum: 103.1;esophagus: 24.6;gallbladder: 24.5;liver: 97.8;small intestine: 88.1;stomach: 62.2,tonsil: 6.2,Cell line enhanced,,BEWO: 3.0
48,DMGDH,,ENSG00000132837,Dimethylglycine dehydrogenase,5,78997606-79236038,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA036441, HPA036442, HPA077849",Enhanced,,Supported,Mitochondria,"Renal cancer:1.17e-5 (favourable), Liver cancer:5.32e-5 (favourable)",Group enriched,Group enriched,11,kidney: 179.1;liver: 146.2,epididymis: 14.9,Cell line enhanced,,BJ hTERT+: 2.9;Hep G2: 5.2
49,F5,,ENSG00000198734,Coagulation factor V,1,169514166-169586588,"Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins",Evidence at protein level,HPA002036,Uncertain,,Approved,Golgi apparatus,Stomach cancer:3.39e-4 (unfavourable),Tissue enriched,Group enriched,11,gallbladder: 28.4;liver: 93.7;placenta: 68.2,fallopian tube: 5.9,Cell line enriched,7.0,Hep G2: 22.8
50,GPR88,,ENSG00000181656,G protein-coupled receptor 88,1,100538137-100542018,"Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins",Evidence at transcript level,HPA007488,,Approved,,,,Tissue enriched,Group enriched,11,breast: 9.4;cerebral cortex: 3.1;liver: 4.9;ovary: 3.1;parathyroid gland: 4.9;spleen: 14.4,prostate: 0.6,Group enriched,8.0,HSkMC: 1.1;SCLC-21H: 2.3
51,KHK,,ENSG00000138030,Ketohexokinase,2,27086747-27100772,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA007040,Enhanced,,Approved,Cytosol,Endometrial cancer:7.62e-8 (unfavourable),Group enriched,Group enriched,11,duodenum: 113.1;kidney: 111.2;liver: 97.3;small intestine: 133.2,cerebral cortex: 10.1,Cell line enhanced,,Hep G2: 32.5
52,SRD5A2,,ENSG00000277893,Steroid 5 alpha-reductase 2,2,31522480-31581067,"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins",Evidence at protein level,,,,,,,Group enriched,Group enriched,11,epididymis: 27.9;fallopian tube: 31.6;liver: 30.6;prostate: 26.6;seminal vesicle: 24.5,testis: 2.5,Cell line enhanced,,RT4: 1.2
53,ABCC2,"CMOAT, cMRP, DJS, MRP2",ENSG00000023839,ATP binding cassette subfamily C member 2,10,99782732-99852192,"Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA004860, CAB037271",Enhanced,,,,Renal cancer:1.93e-5 (unfavourable),Tissue enhanced,Group enriched,10,duodenum: 43.5;gallbladder: 42.7;kidney: 20.9;liver: 67.6;small intestine: 49.5,breast: 4.4,Cell line enhanced,,A549: 203.8;Hep G2: 155.8
54,ACMSD,,ENSG00000153086,Aminocarboxymuconate semialdehyde decarboxylase,2,134838547-134902034,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA010533, HPA011179",Enhanced,,,,Renal cancer:2.39e-4 (favourable),Group enriched,Group enriched,10,kidney: 137.3;liver: 80.2,gallbladder: 10.8,Cell line enriched,16.0,RPTEC TERT1: 19.7
55,GLYAT,"ACGNAT, GAT",ENSG00000149124,Glycine-N-acyltransferase,11,58640426-58731974,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA040251, HPA044094",Enhanced,,,,Renal cancer:1.31e-6 (favourable),Group enriched,Group enriched,10,kidney: 584.9;liver: 355.3,adipose tissue: 47.4,Mixed,,
56,NR1I2,"BXR, ONR1, PAR2, PXR, SXR",ENSG00000144852,Nuclear receptor subfamily 1 group I member 2,3,119780484-119818485,"FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA029309, HPA055121, HPA073926",,,Enhanced,Nucleoplasm,,Group enriched,Group enriched,10,colon: 10.3;duodenum: 27.2;gallbladder: 6.4;liver: 20.0;rectum: 10.7;small intestine: 30.0,stomach: 1.7,Group enriched,7.0,Hep G2: 9.8;RH-30: 3.3
57,PLA2G12B,PLA2G13,ENSG00000138308,Phospholipase A2 group XIIB,10,72935170-72954778,"Plasma proteins, Predicted secreted proteins, RAS pathway related proteins",Evidence at protein level,"HPA057745, HPA059562",Approved,,Approved,Vesicles,,Tissue enriched,Group enriched,10,duodenum: 35.2;kidney: 19.0;liver: 49.9;small intestine: 45.9,lung: 3.9,Group enriched,6.0,CACO-2: 10.3;Hep G2: 14.2
58,C6,,ENSG00000039537,Complement C6,5,41142234-41261438,"Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted secreted proteins, Transporters",Evidence at protein level,"HPA043823, CAB069427",Enhanced,,,,Renal cancer:4.31e-4 (favourable),Group enriched,Group enriched,9,fallopian tube: 73.5;liver: 358.3,heart muscle: 23.4,Group enriched,11.0,ASC diff: 3.2;ASC TERT1: 4.5;HSkMC: 12.3
59,CDHR5,"FLJ20219, MU-PCDH, MUCDHL, MUPCDH",ENSG00000099834,Cadherin related family member 5,11,616565-626078,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA009081, HPA009173, CAB025004",Enhanced,,,,,Group enriched,Group enriched,9,colon: 41.7;duodenum: 82.7;kidney: 23.6;liver: 21.0;rectum: 54.3;small intestine: 64.3,gallbladder: 5.3,Cell line enhanced,,CACO-2: 2.1
60,GNMT,,ENSG00000124713,Glycine N-methyltransferase,6,42960758-42963880,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA027501,Enhanced,,Approved,Cytosol,Liver cancer:1.86e-4 (favourable),Group enriched,Group enriched,9,liver: 155.0;pancreas: 55.8;prostate: 32.7,breast: 9.4,Cell line enhanced,,Hep G2: 5.7;SCLC-21H: 11.3;T-47d: 5.8
61,HSD11B1,"HSD11, HSD11B, SDR26C1",ENSG00000117594,Hydroxysteroid 11-beta dehydrogenase 1,1,209686178-209734950,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA047729,Enhanced,,,,Renal cancer:1.97e-10 (unfavourable),Tissue enriched,Group enriched,9,liver: 492.5;placenta: 105.1,ovary: 31.6,Group enriched,6.0,ASC diff: 678.2;HHSteC: 173.0
62,RIDA,"HRSP12, P14.5, PSP, UK114",ENSG00000132541,Reactive intermediate imine deaminase A homolog,8,98102344-98117241,"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA022856, HPA023489",Enhanced,,,,Liver cancer:9.61e-6 (favourable),Expressed in all,Group enriched,9,kidney: 454.6;liver: 698.7,cerebral cortex: 62.3,Expressed in all,,
63,ASCL1,"ASH1, bHLHa46, HASH1",ENSG00000139352,Achaete-scute family bHLH transcription factor 1,12,102957686-102960516,"Predicted secreted proteins, Transcription factors",Evidence at protein level,HPA029217,Enhanced,,,,,Group enriched,Group enriched,8,cerebral cortex: 16.2;liver: 6.4,adrenal gland: 1.4,Group enriched,23.0,SCLC-21H: 63.4;SH-SY5Y: 30.9
64,CLEC4M,"CD209L, CD299, DC-SIGN2, DC-SIGNR, DCSIGNR, HP10347, LSIGN",ENSG00000104938,C-type lectin domain family 4 member M,19,7763149-7769605,"CD markers, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB033689, CAB033691, HPA042661",Supported,,,,,Not detected,Group enriched,8,liver: 34.7;lymph node: 20.3;placenta: 12.4,testis: 2.9,Not detected,,
65,CLRN3,"MGC32871, TMEM12, USH3AL1",ENSG00000180745,Clarin 3,10,127877841-127892947,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA014482,Approved,,,,Stomach cancer:8.98e-4 (favourable),Group enriched,Group enriched,8,colon: 69.9;duodenum: 73.3;gallbladder: 23.6;kidney: 44.3;liver: 40.4;rectum: 76.3;small intestine: 97.5,appendix: 7.2,Cell line enriched,6.0,CACO-2: 1.9
66,COLEC10,CL-L1,ENSG00000184374,Collectin subfamily member 10,8,118995452-119106582,"Plasma proteins, Predicted secreted proteins",Evidence at protein level,,,,,,Liver cancer:5.79e-4 (favourable),Mixed,Group enriched,8,liver: 51.2;placenta: 26.0,thyroid gland: 5.0,Group enriched,6.0,BJ hTERT+: 5.2;HHSteC: 2.1;SK-BR-3: 8.4
67,CYP1A1,"CP11, CYP1, P1-450, P450-C, P450DX",ENSG00000140465,Cytochrome P450 family 1 subfamily A member 1,15,74719542-74725610,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,CAB018654,Uncertain,,,,,Group enriched,Group enriched,8,liver: 33.9;small intestine: 20.5;urinary bladder: 80.8,breast: 5.7,Cell line enhanced,,CACO-2: 30.3;hTCEpi: 14.0;HUVEC TERT2: 15.7
68,ETNPPL,AGXT2L1,ENSG00000164089,Ethanolamine-phosphate phospho-lyase,4,108742040-108763054,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA044546, HPA072938",Approved,,Approved,Nucleus,Glioma:1.31e-4 (favourable),Group enriched,Group enriched,8,cerebral cortex: 141.2;liver: 98.6,stomach: 15.2,Cell line enhanced,,HeLa: 3.8;Hep G2: 1.5;NTERA-2: 1.1
69,HAL,HIS,ENSG00000084110,Histidine ammonia-lyase,12,95972662-95996365,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA038547, HPA038548",Enhanced,,Uncertain,Cytosol,,Tissue enriched,Group enriched,8,liver: 51.2;skin: 72.5,bone marrow: 7.4,Cell line enhanced,,BEWO: 2.1;THP-1: 7.4
70,IDO2,INDOL1,ENSG00000188676,"Indoleamine 2,3-dioxygenase 2",8,39934614-40016391,Predicted intracellular proteins,Evidence at protein level,,,,,,,Not detected,Group enriched,8,liver: 2.7;placenta: 5.9,"appendix,lymph node,testis: 0.5",Not detected,,
71,PFKFB1,PFRX,ENSG00000158571,"6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 1",X,54932961-54998534,"Enzymes, Predicted intracellular proteins",Evidence at protein level,,,,,,,Tissue enriched,Group enriched,8,adipose tissue: 30.1;liver: 18.7;skeletal muscle: 39.3,breast: 3.8,Cell line enhanced,,ASC diff: 5.9;Hep G2: 2.4
72,SEC14L4,"dJ130H16.5, TAP3",ENSG00000133488,SEC14 like lipid binding 4,22,30488913-30505711,Predicted intracellular proteins,Evidence at protein level,HPA069748,,,Approved,Centrosome,,Tissue enhanced,Group enriched,8,bone marrow: 5.0;liver: 10.3;lung: 6.9;parathyroid gland: 10.5;testis: 7.1,adrenal gland: 0.9,Cell line enhanced,,A549: 6.7;BEWO: 36.9;SiHa: 9.8
73,ATF5,,ENSG00000169136,Activating transcription factor 5,19,49928702-49933935,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA030187,Uncertain,,Supported,Nucleoplasm<br>Cytosol,"Renal cancer:3.39e-7 (unfavourable), Cervical cancer:1.14e-4 (favourable), Endometrial cancer:1.16e-4 (unfavourable)",Tissue enriched,Group enriched,7,liver: 387.6;thyroid gland: 190.2,appendix: 42.4,Expressed in all,,
74,CES1,"CEH, CES1A1, CES1A2, CES2, HMSE, HMSE1, SES1",ENSG00000198848,Carboxylesterase 1,16,55802851-55833337,"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA012023, HPA046717",Enhanced,,Enhanced,Endoplasmic reticulum,Urothelial cancer:9.92e-4 (unfavourable),Tissue enriched,Group enriched,7,gallbladder: 399.2;liver: 1099.9;lung: 229.9,adipose tissue: 79.7,Group enriched,5.0,Hep G2: 414.0;THP-1: 439.1;U-937: 102.6
75,EHHADH,ECHD,ENSG00000113790,Enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase,3,185190624-185281990,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA036401, HPA042021",Enhanced,,,,Renal cancer:1.28e-5 (favourable),Group enriched,Group enriched,7,kidney: 148.6;liver: 173.1,duodenum: 21.4,Mixed,,
76,FABP1,L-FABP,ENSG00000163586,Fatty acid binding protein 1,2,88122982-88128116,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB002305, HPA028275",Enhanced,,Approved,Nucleoplasm<br>Cytosol,,Group enriched,Group enriched,7,colon: 4552.0;duodenum: 4123.5;liver: 5672.8;rectum: 3081.5;small intestine: 4506.9,kidney: 602.3,Group enriched,6.0,CACO-2: 84.1;Hep G2: 221.3
77,GCGR,GGR,ENSG00000215644,Glucagon receptor,17,81804132-81814013,"FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA071228,,,Approved,Golgi apparatus,,Tissue enhanced,Group enriched,7,adrenal gland: 6.6;kidney: 8.4;liver: 20.8;parathyroid gland: 8.0,skin: 1.6,Cell line enhanced,,HeLa: 1.2;MCF7: 2.2;SK-BR-3: 1.8;U-87 MG: 2.7
78,IGSF23,,ENSG00000216588,Immunoglobulin superfamily member 23,19,44613630-44636781,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at transcript level,"HPA051811, HPA054591",Uncertain,,Approved,Nucleus<br>Cell Junctions,Liver cancer:7.20e-6 (favourable),Tissue enriched,Group enriched,7,duodenum: 15.2;liver: 13.0;small intestine: 17.4,testis: 2.3,Cell line enhanced,,CACO-2: 9.0;Hep G2: 4.4;SiHa: 5.2
79,PIPOX,LPIPOX,ENSG00000179761,Pipecolic acid and sarcosine oxidase,17,28950513-29057220,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,,,,,,Pancreatic cancer:1.49e-4 (favourable),Group enriched,Group enriched,7,kidney: 137.9;liver: 235.9,epididymis: 26.0,Group enriched,5.0,AF22: 30.7;Hep G2: 65.9;NTERA-2: 61.7;RH-30: 85.6
80,REEP6,"C19orf32, DP1L1, FLJ25383, Yip2f",ENSG00000115255,Receptor accessory protein 6,19,1490747-1497927,"Disease related genes, Predicted membrane proteins",Evidence at protein level,"HPA003895, HPA048015",Enhanced,,Supported,Endoplasmic reticulum,,Expressed in all,Group enriched,7,adrenal gland: 48.2;duodenum: 166.1;liver: 76.1;small intestine: 167.0;testis: 181.2,prostate: 19.3,Cell line enhanced,,K-562: 101.6;T-47d: 84.9
81,SULT1E1,"EST, STE",ENSG00000109193,Sulfotransferase family 1E member 1,4,69810780-69860152,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA028213, HPA028728, CAB047344",Enhanced,,Uncertain,Nuclear membrane<br>Cytosol,Cervical cancer:4.06e-4 (favourable),Mixed,Group enriched,7,duodenum: 27.7;liver: 18.7;skin: 7.6;small intestine: 29.7,adrenal gland: 3.1,Group enriched,17.0,HHSteC: 59.4;HSkMC: 23.3;hTCEpi: 19.7;HUVEC TERT2: 16.9
82,TBX15,TBX14,ENSG00000092607,T-box 15,1,118883046-118989556,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA052245, HPA053713",Uncertain,,Approved,Nucleoplasm<br>Centrosome,Renal cancer:5.57e-8 (unfavourable),Mixed,Group enriched,7,adipose tissue: 17.0;breast: 8.9;liver: 24.1;skeletal muscle: 42.2,lymph node: 3.1,Cell line enhanced,,ASC diff: 36.8;BJ hTERT+ SV40 Large T+ RasG12V: 20.9;fHDF/TERT166: 22.5;HSkMC: 28.3;RH-30: 29.4;U-2197: 26.3
83,UGT2A1,,ENSG00000173610,UDP glucuronosyltransferase family 2 member A1 complex locus,4,69588417-69653249,"Enzymes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA017261, HPA045108",Uncertain,,,,,Tissue enhanced,Group enriched,7,kidney: 8.1;liver: 5.5,skin: 0.9,Not detected,,
84,ADGRG7,"FLJ14454, GPR128",ENSG00000144820,Adhesion G protein-coupled receptor G7,3,100609589-100695479,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,,,,,,,Tissue enhanced,Group enriched,6,duodenum: 42.8;liver: 12.5;small intestine: 42.9,colon: 5.3,Not detected,,
85,ADH1B,ADH2,ENSG00000196616,"Alcohol dehydrogenase 1B (class I), beta polypeptide",4,99304964-99352760,"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA047814, HPA060902",Supported,,Approved,Plasma membrane<br>Cytosol,Renal cancer:7.87e-4 (unfavourable),Tissue enriched,Group enriched,6,adipose tissue: 1624.6;liver: 3000.2,lung: 388.5,Cell line enriched,7.0,ASC diff: 4511.9
86,BHMT2,,ENSG00000132840,Betaine--homocysteine S-methyltransferase 2,5,79069717-79089466,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA044573,Enhanced,,,,,Group enriched,Group enriched,6,kidney: 362.7;liver: 238.5,epididymis: 46.2,Cell line enhanced,,Hep G2: 53.5;hTEC/SVTERT24-B: 46.4;U-87 MG: 18.9
87,C8G,,ENSG00000176919,Complement C8 gamma chain,9,136945246-136946974,"Plasma proteins, Predicted secreted proteins",Evidence at protein level,HPA046269,Approved,,Uncertain,Endoplasmic reticulum,Colorectal cancer:2.99e-4 (unfavourable),Tissue enriched,Group enriched,6,duodenum: 49.8;liver: 106.5;small intestine: 34.5,gallbladder: 9.8,Cell line enriched,16.0,HMC-1: 139.2
88,CETP,BPIFF,ENSG00000087237,Cholesteryl ester transfer protein,16,56961850-56983845,"Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins, Transporters",Evidence at protein level,,,,,,,Mixed,Group enriched,6,adipose tissue: 36.9;liver: 21.7;lymph node: 46.3;placenta: 50.4;spleen: 77.7,thyroid gland: 8.4,Cell line enhanced,,HEL: 2.4;HUVEC TERT2: 3.6;TIME: 2.1
89,CLEC4G,"LSECtin, UNQ431",ENSG00000182566,C-type lectin domain family 4 member G,19,7728957-7733906,Predicted membrane proteins,Evidence at protein level,"CAB003789, HPA014044",Enhanced,,,,,Mixed,Group enriched,6,adipose tissue: 18.7;liver: 27.6;lymph node: 16.8,urinary bladder: 3.4,Not detected,,
90,CYP4F2,,ENSG00000186115,Cytochrome P450 family 4 subfamily F member 2,19,15878023-15898120,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA014048, HPA017265, HPA058960",Supported,,,,,Tissue enriched,Group enriched,6,duodenum: 78.2;epididymis: 28.0;kidney: 39.3;liver: 84.6;small intestine: 84.3,prostate: 10.4,Cell line enhanced,,Hep G2: 2.5
91,DCXR,"DCR, KIDCR, SDR20C1",ENSG00000169738,Dicarbonyl and L-xylulose reductase,17,82035136-82037732,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA023371, HPA023863",Enhanced,,Uncertain,Nucleoli<br>Microtubules,"Renal cancer:2.13e-4 (favourable), Pancreatic cancer:4.70e-4 (favourable)",Expressed in all,Group enriched,6,epididymis: 297.5;kidney: 217.3;liver: 640.9;prostate: 137.5,adipose tissue: 56.7,Expressed in all,,
92,DNMT3L,MGC1090,ENSG00000142182,DNA methyltransferase 3 like,21,44246339-44262216,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA055234, HPA066780",Uncertain,,Approved,Nuclear speckles,,Tissue enriched,Group enriched,6,kidney: 7.2;liver: 10.4;lymph node: 2.3,spleen: 1.1,Cell line enriched,7.0,BEWO: 40.9
93,FCN3,"FCNH, HAKA1",ENSG00000142748,Ficolin 3,1,27369112-27374824,"Disease related genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,CAB025945,Approved,,,,,Mixed,Group enriched,6,liver: 144.1;lung: 266.5,placenta: 33.0,Not detected,,
94,GATM,AGAT,ENSG00000171766,Glycine amidinotransferase,15,45361124-45402327,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA026077,Enhanced,,Supported,Mitochondria,Renal cancer:1.38e-4 (favourable),Expressed in all,Group enriched,6,kidney: 1904.2;liver: 1291.1;pancreas: 573.9,ovary: 195.7,Cell line enhanced,,RH-30: 190.4;U-266/70: 92.4;U-266/84: 115.1
95,GHR,GHBP,ENSG00000112964,Growth hormone receptor,5,42423777-42721878,"Disease related genes, FDA approved drug targets, Predicted membrane proteins",Evidence at protein level,"HPA045339, HPA057705",Enhanced,,Supported,Plasma membrane<br>Cytosol<br>Cytoplasmic bodies,Liver cancer:2.73e-6 (favourable),Mixed,Group enriched,6,adipose tissue: 91.4;liver: 110.5,prostate: 18.0,Group enriched,7.0,HSkMC: 15.4;T-47d: 52.5
96,HNF4A,"HNF4, MODY, MODY1, NR2A1, TCF14",ENSG00000101076,Hepatocyte nuclear factor 4 alpha,20,44355700-44434596,"Disease related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA004712, CAB019417",Enhanced,,Supported,Nucleoplasm,,Tissue enhanced,Group enriched,6,colon: 58.0;duodenum: 103.0;kidney: 44.7;liver: 51.0;rectum: 47.8;small intestine: 90.9;stomach: 21.9,gallbladder: 9.2,Group enriched,8.0,CACO-2: 126.0;Hep G2: 77.0
97,IGFALS,ALS,ENSG00000099769,Insulin like growth factor binding protein acid labile subunit,16,1790413-1794971,"Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA040692, HPA040948",Approved,,Supported,Nucleoplasm,"Liver cancer:5.97e-4 (favourable), Endometrial cancer:6.06e-4 (unfavourable)",Tissue enhanced,Group enriched,6,liver: 25.0;stomach: 6.6,gallbladder: 2.5,Cell line enhanced,,Hep G2: 1.2;U-266/70: 1.3
98,NEU4,,ENSG00000204099,Neuraminidase 4,2,241808825-241817413,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA037394, HPA037395",Uncertain,,,,,Group enriched,Group enriched,6,bone marrow: 2.4;cerebral cortex: 6.3;colon: 8.3;duodenum: 5.6;liver: 4.1;rectum: 3.7;small intestine: 5.3,"fallopian tube,gallbladder: 0.7",Group enriched,20.0,Hep G2: 26.3;HMC-1: 45.5
99,ONECUT1,"HNF-6, HNF6, HNF6A",ENSG00000169856,One cut homeobox 1,15,52756989-52791078,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA003457,Enhanced,,,,,Group enriched,Group enriched,6,gallbladder: 8.4;liver: 5.9;pancreas: 2.3;testis: 1.8,bone marrow: 0.7,Cell line enhanced,,MCF7: 1.7;WM-115: 1.5
100,PCK2,"PEPCK, PEPCK2",ENSG00000100889,"Phosphoenolpyruvate carboxykinase 2, mitochondrial",14,24094053-24110598,"Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB018734, HPA051162, HPA053502",Enhanced,,Enhanced,Mitochondria,Liver cancer:2.81e-4 (favourable),Expressed in all,Group enriched,6,duodenum: 367.6;kidney: 192.2;liver: 258.6;small intestine: 276.5,colon: 47.0,Expressed in all,,
101,PRAP1,UPA,ENSG00000165828,Proline rich acidic protein 1,10,133347146-133352683,Predicted secreted proteins,Evidence at protein level,"HPA038713, HPA052451",Supported,,Uncertain,Nucleoplasm<br>Vesicles<br>Plasma membrane,,Group enriched,Group enriched,6,duodenum: 928.6;liver: 297.4;small intestine: 1097.7,kidney: 125.6,Group enriched,5.0,CACO-2: 18.2;Hep G2: 64.2
102,SERPINA3,"AACT, ACT",ENSG00000196136,Serpin family A member 3,14,94612377-94624055,"Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA000893, HPA002560, CAB016647",Enhanced,,,,Breast cancer:8.92e-4 (favourable),Mixed,Group enriched,6,"cervix, uterine: 515.4;liver: 2304.3",gallbladder: 228.3,Cell line enriched,6.0,Hep G2: 302.6
103,SLC17A4,KIAA2138,ENSG00000146039,Solute carrier family 17 member 4,6,25754699-25781191,"Predicted membrane proteins, Transporters",Evidence at transcript level,HPA055564,Approved,,,,,Group enriched,Group enriched,6,colon: 20.4;duodenum: 28.6;gallbladder: 25.4;liver: 22.3;rectum: 28.9;small intestine: 35.0,pancreas: 4.2,Cell line enriched,5.0,RPTEC TERT1: 1.1
104,TMPRSS6,FLJ30744,ENSG00000187045,"Transmembrane protease, serine 6",22,37065436-37109563,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,,,,,,Liver cancer:8.16e-6 (favourable),Group enriched,Group enriched,6,liver: 40.8;testis: 8.6,stomach: 4.0,Cell line enhanced,,Hep G2: 3.6;SCLC-21H: 10.1
105,UGT1A6,"GNT1, HLUGP, UGT1F",ENSG00000167165,UDP glucuronosyltransferase family 1 member A6,2,233691607-233773300,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB009819, HPA054065",Enhanced,,,,Liver cancer:2.89e-6 (unfavourable),Tissue enhanced,Group enriched,6,kidney: 75.4;liver: 72.4;urinary bladder: 107.9,esophagus: 15.2,Cell line enhanced,,CACO-2: 44.4;EFO-21: 75.2;HaCaT: 258.5;RT4: 119.0
106,AADAC,"CES5A1, DAC",ENSG00000114771,Arylacetamide deacetylase,3,151814037-151828488,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA002911,Approved,,,,"Ovarian cancer:5.58e-6 (favourable), Stomach cancer:2.19e-4 (unfavourable), Pancreatic cancer:5.02e-4 (unfavourable)",Tissue enriched,Group enriched,5,adrenal gland: 150.1;duodenum: 182.4;liver: 386.8;small intestine: 215.8,stomach: 43.5,Cell line enhanced,,A549: 7.3;EFO-21: 3.9;HBEC3-KT: 2.7
107,ACY1,,ENSG00000243989,Aminoacylase 1,3,51983278-51989202,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB003695, HPA036174, HPA036175",Enhanced,,,,"Renal cancer:2.93e-4 (favourable), Urothelial cancer:6.77e-4 (favourable)",Expressed in all,Group enriched,5,duodenum: 130.8;kidney: 356.0;liver: 114.9;small intestine: 103.3,parathyroid gland: 35.0,Mixed,,
108,AKR1C2,"BABP, DD, DD2, DDH2, HAKRD, MCDR2, TDD",ENSG00000151632,Aldo-keto reductase family 1 member C2,10,4987400-5018031,"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB047304, HPA068265",Enhanced,,Approved,Nucleus<br>Nucleoli fibrillar center<br>Endoplasmic reticulum<br>Cytosol,,Group enriched,Group enriched,5,adipose tissue: 330.4;breast: 105.2;esophagus: 94.9;gallbladder: 151.9;liver: 161.4;stomach: 126.5;urinary bladder: 143.0,duodenum: 29.8,Cell line enhanced,,A549: 1864.0;ASC diff: 1674.9;Hep G2: 2661.0;RT4: 940.6
109,AKR7A3,,ENSG00000162482,Aldo-keto reductase family 7 member A3,1,19282558-19289250,Predicted intracellular proteins,Evidence at protein level,HPA064638,,,Approved,Cytosol,Renal cancer:8.80e-7 (favourable),Group enriched,Group enriched,5,duodenum: 170.4;gallbladder: 38.7;kidney: 49.0;liver: 44.8;small intestine: 106.8;stomach: 70.3,colon: 15.9,Cell line enhanced,,SK-BR-3: 12.6
110,AOX1,"AO, AOH1",ENSG00000138356,Aldehyde oxidase 1,2,200585868-200677064,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA040199, HPA040215",Enhanced,,,,Renal cancer:6.05e-5 (favourable),Tissue enriched,Group enriched,5,adrenal gland: 368.8;kidney: 97.5;liver: 432.3,ovary: 56.8,Cell line enhanced,,ASC diff: 241.4;ASC TERT1: 125.7;hTERT-HME1: 56.6
111,CYP2D6,"CPD6, CYP2D, CYP2D7AP, CYP2D7BP, CYP2D7P2, CYP2D8P2, CYP2DL1, P450-DB1, P450C2D",ENSG00000100197,Cytochrome P450 family 2 subfamily D member 6,22,42126499-42130906,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA045223,Enhanced,,Approved,Golgi apparatus,,Tissue enriched,Group enriched,5,duodenum: 3.7;liver: 10.0;small intestine: 13.0,testis: 1.7,Cell line enhanced,,Hep G2: 1.2;HMC-1: 2.2;REH: 1.4;U-266/70: 1.3
112,FOXA3,HNF3G,ENSG00000170608,Forkhead box A3,19,45863989-45873797,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"CAB015154, HPA054034",Uncertain,,Approved,Nucleoplasm,,Mixed,Group enriched,5,colon: 16.7;duodenum: 10.3;liver: 32.5;pancreas: 9.8;rectum: 17.9;small intestine: 13.9;stomach: 33.8,gallbladder: 3.6,Cell line enhanced,,CACO-2: 8.4;HDLM-2: 11.2;Hep G2: 18.9;K-562: 20.1;NTERA-2: 10.8
113,GAMT,"PIG2, TP53I2",ENSG00000130005,Guanidinoacetate N-methyltransferase,19,1397026-1401570,"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA051806,Approved,,,,Stomach cancer:6.57e-4 (unfavourable),Tissue enriched,Group enriched,5,epididymis: 173.0;liver: 158.9;skeletal muscle: 425.6,pancreas: 48.1,Mixed,,
114,GSTA2,GST2,ENSG00000244067,Glutathione S-transferase alpha 2,6,52750089-52763569,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA004342, HPA048934, HPA053817",Supported,,Supported,Cytosol,Renal cancer:1.17e-4 (unfavourable),Group enriched,Group enriched,5,kidney: 651.7;liver: 986.1,gallbladder: 155.6,Group enriched,17.0,CACO-2: 19.6;Hep G2: 12.5
115,LBP,BPIFD2,ENSG00000129988,Lipopolysaccharide binding protein,20,38346356-38377023,"Plasma proteins, Predicted secreted proteins, Transporters",Evidence at protein level,"HPA001508, CAB025905",Approved,,,,"Renal cancer:3.62e-12 (unfavourable), Cervical cancer:5.56e-4 (unfavourable), Stomach cancer:5.76e-4 (unfavourable)",Tissue enriched,Group enriched,5,adipose tissue: 69.3;liver: 264.7,appendix: 31.3,Group enriched,7.0,ASC diff: 6.7;HSkMC: 8.5
116,SLC27A2,"ACSVL1, FACVL1, FATP2, hFACVL1, HsT17226, VLACS, VLCS",ENSG00000140284,Solute carrier family 27 member 2,15,50182196-50236395,"Enzymes, Predicted membrane proteins, Transporters",Evidence at protein level,HPA026089,Enhanced,,,,"Renal cancer:7.48e-6 (favourable), Urothelial cancer:6.40e-4 (favourable)",Tissue enhanced,Group enriched,5,epididymis: 80.1;kidney: 162.3;liver: 145.5,placenta: 24.7,Cell line enhanced,,HaCaT: 78.4;HL-60: 52.3;SCLC-21H: 47.4
117,SLC6A1,"GABATHG, GABATR, GAT1",ENSG00000157103,Solute carrier family 6 member 1,3,10992724-11039247,"Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA013341, CAB022293",Enhanced,,Uncertain,Mitochondria,"Renal cancer:5.05e-6 (unfavourable), Liver cancer:3.20e-4 (favourable)",Group enriched,Group enriched,5,cerebral cortex: 119.4;liver: 50.4,parathyroid gland: 16.0,Not detected,,
118,SMLR1,,ENSG00000256162,Small leucine rich protein 1,6,130827406-130837135,Predicted membrane proteins,Evidence at protein level,HPA066060,Uncertain,,,,,Tissue enriched,Group enriched,5,duodenum: 12.2;liver: 28.9;small intestine: 11.4,kidney: 3.2,Cell line enriched,10.0,Hep G2: 55.1
119,UGT2B15,UGT2B8,ENSG00000196620,UDP glucuronosyltransferase family 2 member B15,4,68646630-68670628,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA045108,Approved,,,,"Urothelial cancer:4.50e-4 (favourable), Liver cancer:9.82e-4 (favourable)",Tissue enriched,Group enriched,5,gallbladder: 110.7;liver: 107.6,small intestine: 20.6,Not detected,,
120,VNN1,Tiff66,ENSG00000112299,Vanin 1,6,132681590-132714049,"Enzymes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,HPA064145,Approved,,,,Renal cancer:2.52e-4 (unfavourable),Tissue enhanced,Group enriched,5,duodenum: 171.4;gallbladder: 174.7;liver: 142.4;small intestine: 106.3,kidney: 27.5,Cell line enhanced,,EFO-21: 10.3
